May 8, 2024: On behalf of NCHR, Diana Zuckerman’s testimony at the House Small Business Committee explains that FDA regulations save lives and saves patients’ financial security and do not interfere with innovation in healthcare.
Read More »On Health Policy
Diana Zuckerman Comments on the U.S. Consumer Product Safety Commission Priorities for FY2025/2026
May 8, 2024: NCHR recommended that Consumer Product Safety Commission FY 2025-26 priorities include reducing exposures to PFAS and other chemicals, lead, and heavy metals in tire crumb used in homes, backyards, daycare, playgrounds, and artificial turf fields.
Read More »Dr. Diana Zuckerman Testimony at the House Small Business Committee Hearing
May 8, 2024: On behalf of NCHR, Diana Zuckerman’s testimony at the House Small Business Committee explains that FDA regulations save lives and saves patients’ financial security and do not interfere with innovation in health care.
Read More »NCHR Comment on Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products
April 29, 2024: NCHR backs FDA’s proposed guidance to collect standardized race/ethnicity data in clinical trials, which is crucial for addressing safety and efficacy disparities. We also urge a new category, mandatory implementation, and improved diversity to ensure accurate representation and meaningful efficacy and safety data
Read More »Patient, Consumer, and Public Health Coalition Letter to Rep. Pallone in Support of the Ban Water Beads Act (H.R. 6468)
May 1, 2024: We strongly support H.R. 6468 which would expedite the removal of water beads from the market to prevent severe injuries and fatalities due to these products.
Read More »